Blafarm, I certainly don't want to get ahead of
Post# of 148167
(Total Views: 528)
Posted On: 04/20/2020 9:09:38 AM
Blafarm,
Yes, the list is amazing. Nader put if well but, maybe, modestly : We will be the next Humira. I think he was thinking not only in the revenue, but, in the many indications of Leronlimab.
Only one will mean Billions of revenue, you name it
Pneumonia, for example, would be huge.
So, I don't think you are going ahead of yourself, by the contrary. We need to monetize an indication (strengthen our financials) and then go full blast with the others. We are close to it.
Quote:
I certainly don't want to get ahead of myself, but I submit that if you were already impressed with the existing long laundry list of potential Leronlimab indications -- you might want to prepare for that list to grow even longer. And it might grow to include some indications that we never considered, and that represent very significant annual revenue.
Yes, the list is amazing. Nader put if well but, maybe, modestly : We will be the next Humira. I think he was thinking not only in the revenue, but, in the many indications of Leronlimab.
Only one will mean Billions of revenue, you name it
Pneumonia, for example, would be huge. So, I don't think you are going ahead of yourself, by the contrary. We need to monetize an indication (strengthen our financials) and then go full blast with the others. We are close to it.
(3)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼